Efficacy and Safety of Parecoxib vs. Indomethacin in Preventing Post-ERCP Pancreatitis

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Pancreatitis, AcuteCholangiopancreatography, Endoscopic Retrograde

Interventions

DRUG

Parecoxib Sodium

Parecoxib Sodium 40 mg administered intravenously 30 minutes before the ERCP procedure.

DRUG

Indomethacin suppository

Indomethacin suppository 100 mg administered rectally 30 minutes before the ERCP procedure.

All Listed Sponsors

lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT06623513 - Efficacy and Safety of Parecoxib vs. Indomethacin in Preventing Post-ERCP Pancreatitis | Biotech Hunter | Biotech Hunter